Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
暂无分享,去创建一个
Yair Lotan | Serge Benayoun | Pierre I Karakiewicz | Hartwig Huland | Vincenzo Serretta | Frank Wians | Hideyuki Akaza | Gerson Lüdecke | C. Roehrborn | Y. Lotan | A. Sagalowsky | H. Huland | S. Shariat | P. Karakiewicz | C. Zippe | M. Marberger | N. Miyanaga | H. Akaza | S. Benayoun | P. Perrotte | F. Wians | C. Mian | Claus G Roehrborn | Shahrokh F Shariat | Marta Sanchez-Carbayo | Craig Zippe | Hans Boman | Roberto Casella | Christine Mian | Martin G Friedrich | Sanaa Eissa | Ihor Sawczuk | Hans Hedelin | Raina Rupesh | Naoto Miyanaga | Arthur I Sagalowsky | Paul Perrotte | Michael J Marberger | V. Serretta | S. Eissa | H. Hedelin | M. Friedrich | I. Sawczuk | G. Lüdecke | R. Casella | M. Sánchez-Carbayo | H. Boman | R. Rupesh
[1] S. Loening,et al. Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.
[2] C. Roehrborn,et al. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.
[3] T. Gasser,et al. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. , 2003, The Journal of urology.
[4] A. Sagalowsky,et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. , 2004, European urology.
[5] Michael W Kattan,et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Messing,et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. , 1996, The Journal of urology.
[7] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[8] T. Gasser,et al. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. , 2000, The Journal of urology.
[9] R. Tibshirani,et al. An Introduction to the Bootstrap , 1995 .
[10] R. Tibshirani,et al. The bootstrap estimate of standard error , 1993 .
[11] V. Serretta,et al. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. , 1999, Urology.
[12] S. Cytron,et al. Effects on pain and anxiety of patients viewing their cystoscopy in addition to a detailed explanation: a controlled study , 2003, BJU international.
[13] G. Vooijs,et al. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. , 1993, Acta cytologica.
[14] Michael W Kattan,et al. Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.
[15] Mira,et al. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder , 1999, BJU international.
[16] A. K. Agarwal,et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. , 1999, The Journal of urology.
[17] Pierre I Karakiewicz,et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Grossman,et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. , 1998, The Journal of urology.
[19] D. Lamm,et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.
[20] K Koiso,et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria , 1999, International journal of urology : official journal of the Japanese Urological Association.
[21] Thomas M. Wheeler,et al. A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer , 1998 .
[22] T. Gasser,et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. , 2004, The Journal of urology.